Swiss National Bank
RCKT icon

Swiss National Bank’s Rocket Pharmaceuticals RCKT Stock Holding History

Swiss National Bank’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-153,700
Closed -$377K – 2355
2025
Q2 		$377K Hold
153,700
– – ﹤0.01% 2325
2025
Q1 		$1.03M Hold
153,700
– – ﹤0.01% 2121
2024
Q4 		$1.93M Buy
153,700
+29,100
+23% +$438K ﹤0.01% 1874
2024
Q3 		$2.3M Hold
124,600
– – ﹤0.01% 1782
2024
Q2 		$2.68M Hold
124,600
– – ﹤0.01% 1661
2024
Q1 		$3.36M Sell
124,600
-8,400
-6% -$239K ﹤0.01% 1547
2023
Q4 		$3.99M Buy
133,000
+9,200
+7% +$203K ﹤0.01% 1430
2023
Q3 		$2.54M Buy
123,800
+2,900
+2% +$52.7K ﹤0.01% 1689
2023
Q2 		$2.4M Sell
120,900
-6,500
-5% -$131K ﹤0.01% 1767
2023
Q1 		$2.18M Sell
127,400
-4,600
-3% -$90.1K ﹤0.01% 1790
2022
Q4 		$2.58M Buy
132,000
+30,500
+30% +$562K ﹤0.01% 1741
2022
Q3 		$1.62M Buy
101,500
+2,800
+3% +$43.7K ﹤0.01% 2013
2022
Q2 		$1.36M Buy
98,700
+7,300
+8% +$87K ﹤0.01% 2181
2022
Q1 		$1.45M Buy
91,400
+7,300
+9% +$126K ﹤0.01% 2215
2021
Q4 		$1.84M Hold
84,100
– – ﹤0.01% 2125
2021
Q3 		$2.51M Buy
84,100
+4,000
+5% +$146K ﹤0.01% 1900
2021
Q2 		$3.55M Buy
80,100
+10,700
+15% +$465K ﹤0.01% 1732
2021
Q1 		$3.08M Buy
69,400
+600
+0.9% +$32.9K ﹤0.01% 1747
2020
Q4 		$3.77M Hold
68,800
– – ﹤0.01% 1533
2020
Q3 		$1.57M Buy
68,800
+1,600
+2% +$39.4K ﹤0.01% 1830
2020
Q2 		$1.41M Buy
67,200
+3,700
+6% +$66.7K ﹤0.01% 1907
2020
Q1 		$886K Buy
63,500
+900
+1% +$17.8K ﹤0.01% 1900
2019
Q4 		$1.43M Buy
62,600
+5,900
+10% +$98.5K ﹤0.01% 1932
2019
Q3 		$661K Buy
56,700
+1,900
+3% +$23.6K ﹤0.01% 2260
2019
Q2 		$822K Buy
54,800
+10,300
+23% +$180K ﹤0.01% 2220
2019
Q1 		$781K Buy
44,500
+6,800
+18% +$107K ﹤0.01% 2201
2018
Q4 		$559K Hold
37,700
– – ﹤0.01% 2319
2018
Q3 		$928K Hold
37,700
– – ﹤0.01% 2183
2018
Q2 		$740K Buy
+37,700
New +$713K ﹤0.01% 2319

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Swiss National Bank's RCKT Position: Q3 2025 in Review

Swiss National Bank sold out of Rocket Pharmaceuticals (RCKT) in Q3 2025, closing a stake of 153,700 shares — an estimated $377K sold.

Swiss National Bank first reported a position in RCKT in Q2 2018 and held it in 29 quarters. The position peaked at $3.99M in Q4 2023. 173 funds tracked by Wall St. Rank hold RCKT as of Q3 2025.

  • Swiss National Bank reported no remaining Rocket Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Swiss National Bank sold 153,700 Rocket Pharmaceuticals shares in Q3 2025, an estimated $377K.
  • Swiss National Bank first reported a position in Rocket Pharmaceuticals in Q2 2018 and held it in 29 quarters.
  • Swiss National Bank's Rocket Pharmaceuticals position peaked at $3.99M in Q4 2023.
  • 173 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2025.

Based on Swiss National Bank's 13F filing for Q3 2025, filed 13 Nov 2025.